{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:04:39Z","timestamp":1789787079082,"version":"4.0.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grant Agency of Charles University","award":["814316"],"award-info":[{"award-number":["814316"]}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["SVV 260 416"],"award-info":[{"award-number":["SVV 260 416"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EFSA-CDN-ERDF","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000841"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000841"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00204-018-2356-z","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T13:03:00Z","timestamp":1542718980000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity"],"prefix":"10.1007","volume":"93","author":[{"given":"Mikul\u00e1\u0161","family":"Sk\u00e1la","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Hanouskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Sk\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-5744","authenticated-orcid":false,"given":"Petra","family":"Matou\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"issue":"7","key":"2356_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrcardio.2016.88","volume":"13","author":"M Bellin","year":"2016","unstructured":"Bellin M, Mummery CL (2016) The cancer\u2019s gone, but did chemotherapy damage your heart? Nat Rev Cardiol 13(7):383\u2013384. https:\/\/doi.org\/10.1038\/nrcardio.2016.88","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"2356_CR2","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1096\/fj.14-253856","volume":"28","author":"BC Bernardo","year":"2014","unstructured":"Bernardo BC, Nguyen SS, Winbanks CE et al (2014) Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J 28(12):5097\u20135110. https:\/\/doi.org\/10.1096\/fj.14-253856","journal-title":"FASEB J"},{"key":"2356_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.taap.2015.11.015","volume":"312","author":"J Calvano","year":"2016","unstructured":"Calvano J, Achanzar W, Murphy B et al (2016) Evaluation of microRNAs-208 and 133a\/b as differential biomarkers of acute cardiac and skeletal muscle toxicity in rats. Toxicol Appl Pharmacol 312:53\u201360. https:\/\/doi.org\/10.1016\/j.taap.2015.11.015","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"2356_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11886-016-0731-z","volume":"18","author":"D Cardinale","year":"2016","unstructured":"Cardinale D, Biasillo G, Cipolla CM (2016) Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep 18(6):51. https:\/\/doi.org\/10.1007\/s11886-016-0731-z","journal-title":"Curr Cardiol Rep"},{"issue":"1\u20132","key":"2356_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/CS20090645","volume":"119","author":"YH Cheng","year":"2010","unstructured":"Cheng YH, Tan N, Yang JA et al (2010) A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci 119(1\u20132):87\u201395. https:\/\/doi.org\/10.1042\/cs20090645","journal-title":"Clin Sci"},{"issue":"3","key":"2356_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","volume":"110","author":"EE Creemers","year":"2012","unstructured":"Creemers EE, Tijsen AJ, Pinto YM (2012) Circulating microRNAs novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110(3):483\u2013495. https:\/\/doi.org\/10.1161\/circresaha.111.247452","journal-title":"Circ Res"},{"issue":"2","key":"2356_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.taap.2014.10.006","volume":"281","author":"VG Desai","year":"2014","unstructured":"Desai VG, Kwekel JC, Vijay V et al (2014) Early biomarkers of doxorubicin-induced heart injury in a mouse model. Toxicol Appl Pharmacol 281(2):221\u2013229. https:\/\/doi.org\/10.1016\/j.taap.2014.10.006","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"2356_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1373\/clinchem.2011.173823","volume":"58","author":"Y Devaux","year":"2012","unstructured":"Devaux Y, Vausort M, Goretti E et al (2012) Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 58(3):559\u2013567. https:\/\/doi.org\/10.1373\/clinchem.2011.173823","journal-title":"Clin Chem"},{"issue":"1\u20132","key":"2356_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11010-017-2999-8","volume":"432","author":"G Doka","year":"2017","unstructured":"Doka G, Malikova E, Galkova K et al (2017) Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy. Mol Cell Biochem 432(1\u20132):79\u201389. https:\/\/doi.org\/10.1007\/s11010-017-2999-8","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"2356_CR10","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/jcp.24942","volume":"230","author":"QL Duan","year":"2015","unstructured":"Duan QL, Yang L, Gong W et al (2015) MicroRNA-214 is upregulated in heart failure patients and suppresses XBP1-mediated endothelial cells angiogenesis. J Cell Physiol 230(8):1964\u20131973. https:\/\/doi.org\/10.1002\/jcp.24942","journal-title":"J Cell Physiol"},{"issue":"12","key":"2356_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861\u2013874. https:\/\/doi.org\/10.1038\/nrg3074","journal-title":"Nat Rev Genet"},{"key":"2356_CR12","doi-asserted-by":"publisher","unstructured":"Farias JG, Molina VM, Carrasco RA et al (2017) Antioxidant therapeutic strategies for cardiovascular conditions associated with oxidative stress. Nutrients 9(9) https:\/\/doi.org\/10.3390\/nu9090966","DOI":"10.3390\/nu9090966"},{"issue":"3","key":"2356_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.pharmthera.2013.03.005","volume":"138","author":"N Ferri","year":"2013","unstructured":"Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R (2013) Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther 138(3):470\u2013484. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.03.005","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2356_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.etap.2011.12.023","volume":"33","author":"J Fu","year":"2012","unstructured":"Fu J, Peng CK, Wang WY, Jin HF, Tang QQ, Wei XT (2012) Let-7g is involved in doxorubicin induced myocardial injury. Environ Toxicol Pharmacol 33(2):312\u2013317. https:\/\/doi.org\/10.1016\/j.etap.2011.12.023","journal-title":"Environ Toxicol Pharmacol"},{"issue":"17","key":"2356_CR15","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1089\/scd.2017.0062","volume":"26","author":"BC Fu","year":"2017","unstructured":"Fu BC, Lang JL, Zhang DY et al (2017) Suppression of miR-34a expression in the myocardium protects against ischemia-reperfusion injury through SIRT1 protective pathway. Stem Cells Dev 26(17):1270\u20131282. https:\/\/doi.org\/10.1089\/scd.2017.0062","journal-title":"Stem Cells Dev"},{"issue":"2","key":"2356_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/toxsci\/kfw090","volume":"152","author":"AH Harrill","year":"2016","unstructured":"Harrill AH, McCullough SD, Wood CE, Kahle JJ, Chorley BN (2016) MicroRNA biomarkers of toxicity in biological matrices. Toxicol Sci 152(2):264\u2013272. https:\/\/doi.org\/10.1093\/toxsci\/kfw090","journal-title":"Toxicol Sci"},{"key":"2356_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tiv.2016.03.009","volume":"34","author":"G Holmgren","year":"2016","unstructured":"Holmgren G, Synnergren J, Andersson CX, Lindahl A, Sartipy P (2016) MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity. Toxicol In Vitro 34:26\u201334. https:\/\/doi.org\/10.1016\/j.tiv.2016.03.009","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"2356_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/cvr\/cvq148","volume":"87","author":"T Horie","year":"2010","unstructured":"Horie T, Ono K, Nishi H et al (2010) Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87(4):656\u2013664. https:\/\/doi.org\/10.1093\/cvr\/cvq148","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2356_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11626-017-0222-6","volume":"54","author":"A Jain","year":"2018","unstructured":"Jain A, Rani V (2018) Anti-hypotensive drug induced cardiotoxicity: an in vitro study. In Vitro Cell Dev Biol Anim 54(2):92\u201398. https:\/\/doi.org\/10.1007\/s11626-017-0222-6","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"11","key":"2356_CR20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2217\/bmm.15.89","volume":"9","author":"I Koturbash","year":"2015","unstructured":"Koturbash I, Tolleson WH, Guo L et al (2015) microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark Med 9(11):1153\u20131176. https:\/\/doi.org\/10.2217\/bmm.15.89","journal-title":"Biomark Med"},{"issue":"11","key":"2356_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2217\/bmm.15.50","volume":"9","author":"J Krauskopf","year":"2015","unstructured":"Krauskopf J, Verheijen M, Kleinjans JC, de Kok TM, Caiment F (2015) Development and regulatory application of microRNA biomarkers. Biomark Med 9(11):1137\u20131151. https:\/\/doi.org\/10.2217\/bmm.15.50","journal-title":"Biomark Med"},{"issue":"4","key":"2356_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1161\/CIRCGENETICS.110.958975","volume":"4","author":"Y Kuwabara","year":"2011","unstructured":"Kuwabara Y, Ono K, Horie T et al (2011) Increased MicroRNA-1 and MicroRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 4(4):446\u2013454. https:\/\/doi.org\/10.1161\/circgenetics.110.958975","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"2356_CR23","doi-asserted-by":"publisher","first-page":"e004653","DOI":"10.1161\/JAHA.116.004653","volume":"6","author":"KJ Leger","year":"2017","unstructured":"Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PPA, Winick NJ (2017) Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. J Am Heart Assoc 6(4):e004653. https:\/\/doi.org\/10.1161\/jaha.116.004653","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2356_CR24","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3892\/etm.2016.3182","volume":"11","author":"JZ Li","year":"2016","unstructured":"Li JZ, Tang XN, Li TT et al (2016) Paeoniflorin inhibits doxorubicin-induced cardiomyocyte apoptosis by downregulating microRNA-1 expression. Exp Ther Med 11(6):2407\u20132412. https:\/\/doi.org\/10.3892\/etm.2016.3182","journal-title":"Exp Ther Med"},{"issue":"7","key":"2356_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/0192623314525684","volume":"42","author":"L Liu","year":"2014","unstructured":"Liu L, Aguirre SA, Evering WEN et al (2014) miR-208a as a biomarker of isoproterenol-induced cardiac injury in Sod2(+\/\u2212) and C57BL\/6J wild-type mice. Toxicol Pathol 42(7):1117\u20131129. https:\/\/doi.org\/10.1177\/0192623314525684","journal-title":"Toxicol Pathol"},{"key":"2356_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2016.12.036","volume":"198","author":"L Liu","year":"2017","unstructured":"Liu L, Ning BB, Cui JG, Zhang T, Chen Y (2017) miR-29c is implicated in the cardioprotective activity of Panax notoginseng saponins against isoproterenol-induced myocardial fibrogenesis. J Ethnopharmacol 198:1\u20134. https:\/\/doi.org\/10.1016\/j.jep.2016.12.036","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"2356_CR27","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1093\/nar\/gkw116","volume":"44","author":"N Ludwig","year":"2016","unstructured":"Ludwig N, Leidinger P, Becker K et al (2016) Distribution of miRNA expression across human tissues. Nucleic Acids Res 44(8):3865\u20133877. https:\/\/doi.org\/10.1093\/nar\/gkw116","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2356_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.recesp.2016.12.032","volume":"70","author":"R Madonna","year":"2017","unstructured":"Madonna R (2017) Early diagnosis and prediction of anticancer drug-induced cardiotoxicity: from cardiac imaging to \u201cOmics\u201d technologies. Rev Espanol Cardiol 70(7):576\u2013582. https:\/\/doi.org\/10.1016\/j.recesp.2016.12.032","journal-title":"Rev Espanol Cardiol"},{"issue":"8","key":"2356_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ejhf.517","volume":"18","author":"FZ Marques","year":"2016","unstructured":"Marques FZ, Vizi D, Khammy O, Mariani JA, Kaye DM (2016) The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail 18(8):1000\u20131008. https:\/\/doi.org\/10.1002\/ejhf.517","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2356_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1517\/17425255.2015.1021687","volume":"11","author":"AK Marrone","year":"2015","unstructured":"Marrone AK, Beland FA, Pogribny IP (2015) The role for microRNAs in drug toxicity and in safety assessment. Expert Opin Drug Metab Toxicol 11(4):601\u2013611. https:\/\/doi.org\/10.1517\/17425255.2015.1021687","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2356_CR31","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.18632\/aging.101250","volume":"9","author":"JA McCubrey","year":"2017","unstructured":"McCubrey JA, Lertpiriyapong K, Steelman LS et al (2017) Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging-US 9(6):1477\u20131536. https:\/\/doi.org\/10.18632\/aging.101250","journal-title":"Aging-US"},{"issue":"1","key":"2356_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0192623312448939","volume":"41","author":"I Mikaelian","year":"2013","unstructured":"Mikaelian I, Scicchitano M, Mendes O, Thomas RA, LeRoy BE (2013) Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs. Toxicol Pathol 41(1):18\u201331. https:\/\/doi.org\/10.1177\/0192623312448939","journal-title":"Toxicol Pathol"},{"issue":"8","key":"2356_CR33","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/eci.12475","volume":"45","author":"PK Min","year":"2015","unstructured":"Min PK, Chan SY (2015) The biology of circulating microRNAs in cardiovascular disease. Eur J Clin Investig 45(8):860\u2013874. https:\/\/doi.org\/10.1111\/eci.12475","journal-title":"Eur J Clin Investig"},{"key":"2356_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/186904","author":"AJ Min","year":"2015","unstructured":"Min AJ, Zhu C, Peng SP, Rajthala S, Costea DE, Sapkota D (2015) MicroRNAs as important players and biomarkers in oral carcinogenesis. Biomed Res Int. https:\/\/doi.org\/10.1155\/2015\/186904","journal-title":"Biomed Res Int"},{"issue":"14","key":"2356_CR35","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","volume":"124","author":"RL Montgomery","year":"2011","unstructured":"Montgomery RL, Hullinger TG, Semus HM et al (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14):1537\u20131547. https:\/\/doi.org\/10.1161\/circulationaha.111.030932","journal-title":"Circulation"},{"key":"2356_CR36","doi-asserted-by":"crossref","unstructured":"Moutinho C, Esteller M (2017) MicroRNAs and epigenetics. In: Croce CM, Fisher PB (eds) Mirna and cancer. Advances in Cancer Research, vol\u00a0135, pp\u00a0189\u2013220","DOI":"10.1016\/bs.acr.2017.06.003"},{"issue":"3","key":"2356_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/aps.2016.142","volume":"38","author":"BB Ning","year":"2017","unstructured":"Ning BB, Zhang Y, Wu DD et al (2017) Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in mice. Acta Pharmacol Sin 38(3):331\u2013341. https:\/\/doi.org\/10.1038\/aps.2016.142","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"2356_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jat.3044","volume":"35","author":"Y Nishimura","year":"2015","unstructured":"Nishimura Y, Kondo C, Morikawa Y et al (2015) Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats. J Appl Toxicol 35(2):173\u2013180. https:\/\/doi.org\/10.1002\/jat.3044","journal-title":"J Appl Toxicol"},{"issue":"3","key":"2356_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12012-016-9393-8","volume":"17","author":"J Novak","year":"2017","unstructured":"Novak J, Sana J, Stracina T, Novakova M, Slaby O (2017) Doxorubicin and liposomal doxorubicin differentially affect expression of miR-208a and let-7g in rat ventricles and atria. Cardiovasc Toxicol 17(3):355\u2013359. https:\/\/doi.org\/10.1007\/s12012-016-9393-8","journal-title":"Cardiovasc Toxicol"},{"issue":"9","key":"2356_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/jat.3185","volume":"35","author":"V Oliveira-Carvalho","year":"2015","unstructured":"Oliveira-Carvalho V, Ferreira LRP, Bocchi EA (2015) Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. J Appl Toxicol 35(9):1071\u20131072. https:\/\/doi.org\/10.1002\/jat.3185","journal-title":"J Appl Toxicol"},{"issue":"6","key":"2356_CR41","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page","year":"2016","unstructured":"Page RL, O\u2019Bryant CL, Cheng D et al (2016) Drugs that may cause or exacerbate heart failure a scientific statement from the American Heart Association. Circulation 134(6):E32\u2013E69. https:\/\/doi.org\/10.1161\/cir.0000000000000426","journal-title":"Circulation"},{"issue":"38","key":"2356_CR42","doi-asserted-by":"publisher","first-page":"62312","DOI":"10.18632\/oncotarget.11468","volume":"7","author":"E Piegari","year":"2016","unstructured":"Piegari E, Russo R, Cappetta D et al (2016) MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat. Oncotarget 7(38):62312\u201362326. https:\/\/doi.org\/10.18632\/oncotarget.11468","journal-title":"Oncotarget"},{"issue":"10","key":"2356_CR43","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1464-410X.2012.11134.x","volume":"110","author":"PP Rainer","year":"2012","unstructured":"Rainer PP, Doleschal B, Kirk JA et al (2012) Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes. BJU Int 110(10):1455\u20131462. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11134.x","journal-title":"BJU Int"},{"issue":"4","key":"2356_CR44","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.18632\/oncotarget.14355","volume":"8","author":"VOC Rigaud","year":"2017","unstructured":"Rigaud VOC, Ferreira LRP, Ayub-Ferreira SM et al (2017) Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget 8(4):6994\u20137002. https:\/\/doi.org\/10.18632\/oncotarget.14355","journal-title":"Oncotarget"},{"key":"2356_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.89","author":"L Roca-Alonso","year":"2015","unstructured":"Roca-Alonso L, Castellano L, Mills A et al (2015) Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in beta-adrenergic signaling and enhances apoptosis. Cell Death Disease. https:\/\/doi.org\/10.1038\/cddis.2015.89","journal-title":"Cell Death Disease"},{"issue":"12","key":"2356_CR46","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/heartjnl-2013-305402","volume":"101","author":"SPR Romaine","year":"2015","unstructured":"Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ (2015) MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart 101(12):921\u2013928. https:\/\/doi.org\/10.1136\/heartjnl-2013-305402","journal-title":"Heart"},{"key":"2356_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.phrs.2017.05.029","volume":"157","author":"A Rotini","year":"2018","unstructured":"Rotini A, Martinez-Sarra E, Pozzo E, Sarripaolesi M (2018) Interactions between microRNAs and long non-coding RNAs in cardiac development and repair. Pharmacol Res 157:58\u201366. https:\/\/doi.org\/10.1016\/j.phrs.2017.05.029","journal-title":"Pharmacol Res"},{"issue":"1","key":"2356_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","volume":"23","author":"C Ruggeri","year":"2018","unstructured":"Ruggeri C, Gioffre S, Achilli F, Colombo GI, D\u2019Alessandra Y (2018) Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients. Heart Fail Rev 23(1):109\u2013122. https:\/\/doi.org\/10.1007\/s10741-017-9653-0","journal-title":"Heart Fail Rev"},{"issue":"6","key":"2356_CR49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.hlc.2014.01.001","volume":"23","author":"ASM Sayed","year":"2014","unstructured":"Sayed ASM, Xia K, Salma U, Yang TL, Peng J (2014) Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases. Heart Lung Circ 23(6):503\u2013510. https:\/\/doi.org\/10.1016\/j.hlc.2014.01.001","journal-title":"Heart Lung Circ"},{"issue":"2","key":"2356_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1517\/17425255.2014.856881","volume":"10","author":"BK Singh","year":"2014","unstructured":"Singh BK, Haque SE, Pillai KK (2014) Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity. Expert Opin Drug Metab Toxicol 10(2):143\u2013156. https:\/\/doi.org\/10.1517\/17425255.2014.856881","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"2356_CR51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2165\/00002018-200629070-00003","volume":"29","author":"L Slordal","year":"2006","unstructured":"Slordal L, Spigset O (2006) Heart failure induced by non-cardiac drugs. Drug Saf 29(7):567\u2013586","journal-title":"Drug Saf"},{"key":"2356_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/srep18351","author":"M Sun","year":"2015","unstructured":"Sun M, Yu HY, Zhang YY, Li ZJ, Gao W (2015) MicroRNA-214 mediates isoproterenol-induced proliferation and collagen synthesis in cardiac fibroblasts. Sci Rep. https:\/\/doi.org\/10.1038\/srep18351","journal-title":"Sci Rep"},{"issue":"6","key":"2356_CR53","first-page":"5","volume":"17","author":"J Tabernero","year":"2011","unstructured":"Tabernero J, Brana I (2011) Cardiotoxicity induced by anticancer drugs. EJHP Pract 17(6):5\u20137","journal-title":"EJHP Pract"},{"issue":"4","key":"2356_CR54","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/cvr\/cvn137","volume":"79","author":"T Thum","year":"2008","unstructured":"Thum T, Catalucci D, Bauersachs J (2008) MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 79(4):562\u2013570. https:\/\/doi.org\/10.1093\/cvr\/cvn137","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2356_CR55","first-page":"115","volume":"47","author":"VK Todorova","year":"2017","unstructured":"Todorova VK, Makhoul I, Wei JN, Klimberg VS (2017) Circulating miRNA profiles of doxorubicin-induced cardiotoxicity in breast cancer patients. Ann Clin Lab Sci 47(2):115\u2013119","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"2356_CR56","doi-asserted-by":"publisher","first-page":"14511","DOI":"10.3390\/ijms160714511","volume":"16","author":"ZY Tong","year":"2015","unstructured":"Tong ZY, Jiang BM, Wu YY et al (2015) MiR-21 protected cardiomyocytes against doxorubicin-induced apoptosis by targeting BTG2. Int J Mol Sci 16(7):14511\u201314525. https:\/\/doi.org\/10.3390\/ijms160714511","journal-title":"Int J Mol Sci"},{"key":"2356_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/597032","author":"H Tony","year":"2015","unstructured":"Tony H, Yu KW, Zeng QT (2015) MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2015\/597032","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"2356_CR58","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s00259-013-2596-3","volume":"41","author":"YF Tu","year":"2014","unstructured":"Tu YF, Wan L, Zhao DL et al (2014) In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging. Eur J Nucl Med Mol Imaging 41(5):972\u2013984. https:\/\/doi.org\/10.1007\/s00259-013-2596-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2356_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2090","author":"A Ucar","year":"2012","unstructured":"Ucar A, Gupta SK, Fiedler J et al (2012) The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms2090","journal-title":"Nat Commun"},{"key":"2356_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040395","author":"C Vacchi-Suzzi","year":"2012","unstructured":"Vacchi-Suzzi C, Bauer Y, Berridge BR et al (2012) Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLos One. https:\/\/doi.org\/10.1371\/journal.pone.0040395","journal-title":"PLos One"},{"issue":"9","key":"2356_CR61","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"ZV Varga","year":"2015","unstructured":"Varga ZV, Ferdinandy P, Liaudet L, Pacher P (2015) Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 309(9):H1453\u2013H1467. https:\/\/doi.org\/10.1152\/ajpheart.00554.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2356_CR62","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCRESAHA.116.308434","volume":"120","author":"J Viereck","year":"2017","unstructured":"Viereck J, Thum T (2017) Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res 120(2):381\u2013399. https:\/\/doi.org\/10.1161\/circresaha.116.308434","journal-title":"Circ Res"},{"issue":"1","key":"2356_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/mmr.2016.5977","volume":"15","author":"Y Wang","year":"2017","unstructured":"Wang Y, Li M, Xu L et al (2017) Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. Mol Med Rep 15(1):359\u2013365. https:\/\/doi.org\/10.3892\/mmr.2016.5977","journal-title":"Mol Med Rep"},{"key":"2356_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejphar.2016.05.007","volume":"784","author":"QB Yang","year":"2016","unstructured":"Yang QB, Cui JG, Wang PW et al (2016) Changes in interconnected pathways implicating microRNAs are associated with the activity of apocynin in attenuating myocardial fibrogenesis. Eur J Pharmacol 784:22\u201332. https:\/\/doi.org\/10.1016\/j.ejphar.2016.05.007","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2356_CR65","doi-asserted-by":"publisher","first-page":"192","DOI":"10.18632\/aging.100876","volume":"8","author":"ZW Yin","year":"2016","unstructured":"Yin ZW, Zhao YR, Li HP et al (2016) miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway. Aging-US 8(1):192\u2013207. https:\/\/doi.org\/10.18632\/aging.100876","journal-title":"Aging-US"},{"key":"2356_CR66","doi-asserted-by":"crossref","unstructured":"Yokoi T, Nakajima M (2013) microRNAs as mediators of drug toxicity. In: Insel PA (ed) Annual review of pharmacology and toxicology, vol\u00a053, p\u00a0377\u2013400","DOI":"10.1146\/annurev-pharmtox-011112-140250"},{"issue":"6","key":"2356_CR67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/FJC.0000000000000526","volume":"70","author":"WQ Zhang","year":"2017","unstructured":"Zhang WQ, Chang H, Zhang HX, Zhang L (2017) MiR-30e attenuates isoproterenol-induced cardiac fibrosis through suppressing snail\/TGF-beta signaling. J Cardiovasc Pharmacol 70(6):362\u2013368","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"2356_CR68","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1007\/s13277-014-1679-5","volume":"35","author":"ZY Zhao","year":"2014","unstructured":"Zhao ZY, He J, Zhang J et al (2014) Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer. Tumor Biol 35(6):5227\u20135235. https:\/\/doi.org\/10.1007\/s13277-014-1679-5","journal-title":"Tumor Biol"},{"issue":"10","key":"2356_CR69","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.cjca.2015.11.012","volume":"32","author":"XD Zhu","year":"2016","unstructured":"Zhu XD, Chi JY, Liang HH et al (2016) MicroRNA-377 mediates cardiomyocyte apoptosis induced by cyclosporin A. Can J Cardiol 32(10):1249\u20131259. https:\/\/doi.org\/10.1016\/j.cjca.2015.11.012","journal-title":"Can J Cardiol"},{"key":"2356_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12192-y","author":"JN Zhu","year":"2017","unstructured":"Zhu JN, Fu YH, Hu ZQ et al (2017a) Activation of miR-34a-5p\/Sirt1\/p66shc pathway contributes to doxorubicin-induced cardiotoxicity. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-017-12192-y","journal-title":"Sci Rep"},{"issue":"7","key":"2356_CR71","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/10641963.2017.1313853","volume":"39","author":"ML Zhu","year":"2017","unstructured":"Zhu ML, Yin YL, Ping S et al (2017b) Berberine promotes ischemia-induced angiogenesis in mice heart via upregulation of microRNA-29b. Clin Exp Hypertens 39(7):672\u2013679. https:\/\/doi.org\/10.1080\/10641963.2017.1313853","journal-title":"Clin Exp Hypertens"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-018-2356-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-018-2356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-018-2356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T16:29:42Z","timestamp":1605457782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-018-2356-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2356"],"URL":"https:\/\/doi.org\/10.1007\/s00204-018-2356-z","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"26 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}